Rituximab, lenalidomide and pembrolizumab in refractory primary cutaneous diffuse large B cell lymphoma, leg type. (2019) - Di Raimondo, C.; Martinez, X.; Abdulla, F.; Zain, J.; Rosen, S.; Querfeld, C.